Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases

Playback speed

×

Share post

Share post at current time

Share from 0:00

0:00

/

0:00

Transcript

Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases

Recently named CEO Serge Messerlian describes the platform behind this deal, which came with an upfront payment/investment of $13 million.

BiotechTV

Apr 29, 2025

Share

Transcript

Discussion about this video

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts